Stalicla’s series B adds $17.4M for trials in substance abuse disorders, ASD

Stalicla SA Secures $17.4 Million in Series B Funding to Advance Innovative Therapies Subtitle: Funding Enables Progress in Treating Cocaine Misuse Disorder and Autism Spectrum Disorder Date: Friday, Jan. 19, 2024 Source: BioWorld (©2024 BioWorld. Reprinted with permission from Clarivate.) Stalicla SA Achieves First Close of $17.4 Million Series B Round for Therapeutic Development BioWorld, … Read more

STALICLA secures $17.4 Million in Series B Round

STALICLA’s Precision Neuro Advancements propelled by $17.4 Million in Series B Funding Geneva, Switzerland, January 16th, 2024 – STALICLA SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million. Led by SPRIM Global Investments Pte, … Read more